Mallinckrodt OptiMark
This article was originally published in The Gray Sheet
Executive Summary
Magnetic resonance imaging agent shipments are expected to begin in the first quarter of 2000 following FDA approval via new drug application on Dec. 8. The contrast agent is approved for increased enhancement and visualization of lesions of the brain, spine and liver, including tumors